Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it says justify further clinical trials after it impro
A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown.
